Last updated on January 2010

Advanced Stage Non-small Cell Lung Cancer


Brief description of study

Advanced Stage Non-small Cell Lung Cancer

Detailed Study Description

Study to evaluate the long-term safety and efficacy of Darbepoetin Alfa in anemic subjects with Advanced Stage Non-small Cell Lung Cancer receiving multi-cycle chemotherapy.

Patient Inclusion Criteria:

  • Subjects with metastatic (stage IV) Non-small Cell Lung cancer, receiving or about receive first line cyclic chemotherapy, life expectancy >6 months, 18 years and older

Patient Exclusion Criteria:

  • Subjects with a history of brain metastasis, known primary benign or malignant hematologic disorder which can cause anemia, history of or current, active cancer (other than non-small lung), uncontrolled angina, uncontrolled heart failure or uncontrolled chronic cardiac arrhythmia, subject with history of a seizure disorder.

Clinical Study Identifier: TX134695

Contact Investigators or Research Sites near you

Start Over

Dr. Tom Davis

Legacy Pharma Research
Bismarck, ND USA
  Connect »